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Abstract
© 2016, Springer Science+Business Media New York.RNA viruses cause most of the dangerous
communicable diseases. Due to their high mutation rates, RNA viruses quickly evade selective
pressures and can adapt to a new host.  Therefore,  new antiviral  approaches are urgently
needed, which target more than one specific virus variant and which would optimally prevent
development  of  viral  resistance.  Among the family  of  coronaviruses (CoV),  several  human
pathogenic strains (HCoV) are known to cause respiratory diseases and are implied in enteric
diseases. While most strains contribute to common cold-like illnesses, others lead to severe
infections. One of these viruses is the newly emerged (2012), highly pathogenic Middle East
respiratory syndrome coronavirus (MERS-CoV) of zoonotic origin. MERS-CoV causes a severe
respiratory infection with a high mortality rate of  35 %. There is  no specific  treatment or
infection prevention available. Here, we show that the bacterial ribonuclease Binase is able to
inhibit the replication of MERS-CoV and of the low-pathogenic human coronavirus 229E (HCoV-
229E) in cell culture. We demonstrate that at non-toxic concentrations, Binase decreased the
titers of MERS-CoV and HCoV-229E. On a molecular level, Binase treatment reduced (i) the viral
subgenomic  RNAs  and  (ii)  the  viral  nucleocapsidprotein  (N)  and  non-structural  protein  13
(nsp13) accumulation. Furthermore, we show that the quantity of the replication/transcription
complexes within the infected cells is diminished. Thus, the data obtained might allow further
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